EN | UA
EN | UA

Help Support

Back

Efficacy of anti-IL17 and anti-IL23 biologic drugs in real-life patients with scalp psoriasis

Scalp.psoriasis Scalp.psoriasis
Scalp.psoriasis Scalp.psoriasis

A study was carried out to retrospectively compare the effectiveness of anti-interleukin (IL)-23 drugs and anti-IL17 or anti-IL17 receptor A biologics in real-life people suffering from scalp psoriasis.

See All

Key take away

Scalp psoriasis people treated with anti-IL17 agents attained a faster decrease of the lesions. Regarding maintenance of the clinical improvement through the follow-up, the anti-IL23 monoclonal antibodies were slightly superior.

Background

A study was carried out to retrospectively compare the effectiveness of anti-interleukin (IL)-23 drugs and anti-IL17 or anti-IL17 receptor A biologics in real-life people suffering from scalp psoriasis.

Method

This single-center retrospective comparative study recruited 127 people having scalp psoriasis and  baseline scalp Physician Global Assessment ≥3. Overall,  65 people were treated with anti-IL23 agents (risankizumab, tildrakizumab, guselkumab) while 62 people were treated with anti-IL17 agents (brodalumab, ixekizumab, secukinumab). For assessing the percentage of response, statistical analysis through the χ2 test was carried out.

Result

At Week 4, 16, 24, 48, 96, and 144, the responders' percentage of patients under anti-IL23 and anti-IL17 are shown in Table 1:

Conclusion

In patients with a clinical diagnosis of refractory scalp psoriasis, both anti-IL17 and anti-IL23 biologic drugs appeared to be effective.

Source:

Dermatology and Therapy

Article:

Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study

Authors:

Alessandra Narcisi et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: